McDonald's Consumer Scare; Lilly Weight Loss Drug; Qualcomm Falls

On this episode of Stock Movers:
- McDonald's (MCD) shares are lower after US sales fell 3.6% in the first quarter, mainly due to a decline in guest counts, marking the biggest drop in the chain's home market since 2020. The decline is attributed to a deterioration in consumer sentiment, making it harder for restaurants to lure in diners, with low-income customers being particularly affected.
- Eli Lilly (LLY) dropped in the premarket after the drugmaker cut its adjusted earnings per share forecast for the full year. The company also reported first-quarter sales of its blockbuster weight-loss drug, Zepbound, that was in line with expectations. It also follows CVS' drug-benefits unit negotiated a deal to make Novo Nordisk A/S's Wegovy more widely available to its members, replacing Zepbound.
- Qualcomm (QCOM) is falling after its revenue forecast for the period ending in June was $9.9 billion compared to $10.7 billion, which is slightly below analyst estimates. The company's outlook has renewed fears about the impact of tariffs on the smartphone market, which is Qualcomm's largest market. Shares fell over 5% in premarket trading following the announcement, despite the company's efforts to diversify its business beyond the phone market.
- Nvidia (NVDA) shares jumped as Microsoft and Meta beats drove Mag 7 stocks higher. It comes with CEO Jensen Huang also saying he wants the Trump administration to change regulations for exporting AI technology to help American businesses capitalize on opportunities.

See omnystudio.com/listener for privacy information.